How to Deal with a Temporary Suspension and Restarting Your Trial : Our Experiences and lessons Learnt

Funding: VUE is funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (project reference 11/129/183). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.Peer reviewedPublisher PD

Verifying participant-reported clinical outcomes : challenges and implications

The parent trials KAT, REFLUX and CATHETER were all funded by the UK NIHR Health Technology Assessment Programme. RECORD was funded by the UK Medical Research Council. Suzanne Breeman and Lynda Constable are joint first authors.Peer reviewedPublisher PD

User Experiences of a Digital Intervention to Support Total-Skin-Self-Examination by Melanoma Survivors : Nested Qualitative Evaluation Embedded in a Randomized Controlled Trial

Acknowledgments This study was supported by a grant from the Cancer Research UK Population Research Committee project award (C10673/A21685). The views and opinions expressed herein are those of the authors and do not necessarily reflect those of Cancer Research UK. The funder (through their peer review and funding board review process) approved the study proposal, but had no role in the collection, analysis, interpretation of data, or writing of the report. The authors gratefully acknowledge the time and commitment of the participants who provided their time to be interviewed in the study. They also acknowledge the contribution of Billy Brant, Dermatology Nurse Practitioner, National Health System Grampian, to the day-to-day running of the study, for taking part in the interview, and for commenting on the draft manuscript. The authors acknowledge the support of Andrea Fraser of the ASICA trial team from the Centre of Healthcare Randomized Trials at the University of Aberdeen. They also acknowledge Hazel Riley, who transcribed the interviews for analysis.Peer reviewedPublisher PD

It is unprecedented : trial management during the COVID-19 pandemic and beyond

Funding: UKTMN is funded by the Nuffield Department of Population Health (NDPH) at the University of Oxford. Acknowledgments: We thank Graeme MacLennan, Director of the Centre for Health Care Randomised Trials (CHaRT) for the inspiration for this article and UKTMN members for their input into its content. We also thank the huge clinical trial community, both nationally and internationally, for continuing to run clinical trials in these challenging times, and for regulatory agencies to adapting their processes to enable efficiencies.Peer reviewedPublisher PD

Surgical interventions for uterine prolapse and for vault prolapse: the two VUE RCTs

This report The research reported in this issue of the journal was funded by the HTA programme as project number 11/129/183. The contractual start date was in November 2012. The draft report began editorial review in February 2018 and was accepted for publication in August 2018. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.Peer reviewedPublisher PD

The Achieving Self-directed Integrated Cancer Aftercare Intervention for Detection of Recurrent and Second Primary Melanoma in Survivors of Melanoma : Pilot Randomized Controlled Trial

Acknowledgments The authors gratefully acknowledge Joanna Kaniewska, Anne Duncan, and Alison MacDonald (trial management) for their contributions to the protocol and management of the study and Andrea Fraser for secretarial support and data coordination. They also acknowledge Bolanle Birkinns and Susie Hall, who were the research nurses who trained participants and collected case note data at the Aberdeen and Cambridge sites, respectively. The authors thank Mr Mark Forrest and Mr Michael Chung for supporting the digital aspects of the intervention and data collection. They also thank Ms Ilja De Vries and her team from Medical Illustration for providing digital skin maps at the Aberdeen site and Mr Mark Bartley and the Medical Photography team at Addenbrooke’s Media Studio for providing skin maps for the Cambridge participants. The authors also thank Dr Aileen Neilson, who provided advice on collecting data about service use. They also wish to acknowledge the contribution of Rebecca Woods, Patricia Fairbrother, and Dr Doug Smith, who were members of the trial steering committee. The authors also acknowledge the 19 people affected by melanoma who participated in their early feasibility study. This study was supported by a grant from a Cancer Research UK Population Research Committee project award (C10673/A21685). The views and opinions expressed herein are those of the authors and do not necessarily reflect those of Cancer Research UK. The funder (through their peer review and funding board review process) approved the study proposal but had no role in the collection, analysis, or interpretation of the data; the writing of the report; or the decision to submit this paper for publication. The Health Services Research Unit, University of Aberdeen, receives core funding from the Chief Scientist Office of the Scottish Government Health Directorates.Peer reviewedPublisher PD